Navigation Links
GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
Date:3/26/2013

OXFORD, England, March 26, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its cardiac surgery intensive care trial and plans for CE mark testing at two leading MedTech conferences this spring. GlySure CEO Christopher Jones will speak at the inaugural Biovision Investor Conference on March 26th, 2013 in Lyon, France, and at the Investment In Innovation (IN³) Medical Device 360° Conference on April 17th, 2013 in Dublin, Ireland.

Studies have shown that inadequate post-operative blood sugar control in heart surgery patients is associated with an increased risk of major complications and death. GlySure recently completed a trial of its CBGM system on cardiac surgery patients.  The study revealed GlySure's technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across two-to-five days of a patient's stay in ICU, which is key to effectively implementing TGC.

At the Biovision Investor Conference and IN³ Medical Device 360° Conference, Jones will share results of GlySure's cardiac surgery ICU trial and outline the company's plans for CE regulatory trials, which are set to commence this Spring.

Biovision has selected GlySure as one of 35 life science companies to present to its forum of international capital investors and large healthcare companies seeking partnerships and innovation, while the producers of the (IN³) Medical Device 360° Conference have chosen GlySure as one of 35 early stage companies to appear before its global audience of VCs, top investors and corporate acquirers.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Media Contact: Kara Della Vecchia , KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
9. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
Breaking Medicine Technology:
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):